Amylyx Pharmaceuticals (AMLX)
Developing avexitide-led therapies for endocrine and neurodegenerative diseases.
$33.07
vs last close+0.68 (+2.09%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | ≈ 103.12% | 114.90M shares | |
|---|---|---|---|
| 223 holders · as of Jun 30, 2026 · largest filers plus last quarter's tail | |||
| Insiders | 1.47% | 1.64M shares | |
| 6 holders · as of Sep 14, 2026 | |||
| Strategic holders | 5.60% | 6.24M shares | |
| 1 holder · as of Feb 17, 2026 | |||
| Adds to | 110.19% | ||
111.42M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 110.19%; nothing is left for Other.
13F, as of Jun 30, 2026
223 holders · 114.90M shares · 53 new positions · 123 increased · 62 reduced · 15 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| FMR LLC | 16.73M | 15.01% | +97.4K | Aug 13, 2026 |
| BlackRock, Inc. | 8.83M | 7.92% | −1.8K | Aug 7, 2026 |
| Perceptive Advisors LLC | 8.33M | 7.48% | +50.0K | Aug 14, 2026 |
| TCG Crossover Management, LLC | 6.24M | 5.60% | 0 | Aug 14, 2026 |
| Commodore Capital LP | 5.65M | 5.07% | 0 | Aug 14, 2026 |
| Jupiter Topco LLC | 5.24M | 4.70% | +5.24Mnew | Aug 14, 2026 |
| Saturn V Capital Management LLC | 4.62M | 4.15% | +274.2K | Aug 14, 2026 |
| Vanguard Capital Management LLC | 4.22M | 3.79% | +82.6K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| FMR LLC | 15.00% | 16.47M | 13G | Feb 5, 2026 |
| Perceptive Advisors LLC | 7.50% | 8.28M | 13G | May 15, 2026 |
| BlackRock, Inc. | 7.10% | 7.78M | 13G | Jan 21, 2026 |
| TCG Crossover GP II, LLC | 5.70% | 6.24M | 13G | Feb 17, 2026 |
| Commodore Capital LP | 5.10% | 5.65M | 13G | Nov 17, 2025 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 10, 2026 | James M. Fratesofficer: Chief Financial Officer | Sale · 2 lots | 10,810 | $32.36 | 233,625 |
| Sep 10, 2026 | Camille L. Bedrosianofficer: Chief Medical Officer | Sale · 2 lots | 10,028 | $32.40 | 278,064 |
| Sep 10, 2026 | Joshua B. Cohendirector, officer: Co-Chief Executive Officer | Sale · 2 lots | 30,464 | $32.19 | 3,613,123 |
| Sep 10, 2026 | Justin B. Kleedirector, officer: Co-Chief Executive Officer | Sale · 2 lots | 30,464 | $32.18 | 3,613,056 |
| Sep 10, 2026 | Gina Mazzarielloofficer: Chief Legal Officer | Sale · 2 lots | 9,536 | $32.46 | 190,838 |
| Jul 10, 2026 | Gina Mazzarielloofficer: Chief Legal Officer | Sale | 15,000 | $17.61 | 179,090 |
| Jul 9, 2026 | Gina Mazzarielloofficer: Chief Legal Officer | Sale | 15,000 | $18.32 | 194,090 |
| May 21, 2026 | Karen Firestonedirector | Purchase | 3,800 | $13.51 | 66,900 |
| Mar 2, 2026 | Gina Mazzarielloofficer: Chief Legal Officer | Sale | 6,844 | $14.52 | 134,430 |
| Mar 2, 2026 | James M. Fratesofficer: Chief Financial Officer | Sale | 7,909 | $14.52 | 165,638 |
House and Senate disclosures
Not reported.